BLCO (Bausch & Lomb) Valuation Rank


BLCO Bausch & Lomb Corp BLCO
77 GF Score
Price $16.63
GF Value $18.37
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Bausch & Lomb Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Bausch & Lomb Valuation Rank Related Terms

BLCO
77GF Score
Bausch & Lomb Corp BLCO
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bausch & Lomb (BLCO) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued. The current stock price of $16.63 is trading 9.5% below its estimated GF Value™ of $18.37. GuruFocus considers Bausch & Lomb to be Modestly Undervalued.

Key valuation signals for BLCO:

  • Valuation Rank:
  • GF Value™: $18.37 vs. price of $16.63 (9.5% below fair value)
  • GF Score™: 77/100 with 9 warning signs

No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bausch & Lomb Business Description

Other Exchanges S2L:GermanyBLCO:Canada
Address 520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score

Get the complete analysis for BLCO

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.63
Price
$18.37
GF Value